NewsBur
No Result
View All Result
Tuesday, January 26, 2021
  • Home
  • Morning News
  • Market News
  • Analyst Actions
  • Trending Stocks
Subscribe
Newsbur
  • Home
  • Morning News
  • Market News
  • Analyst Actions
  • Trending Stocks
No Result
View All Result
Newsbur
No Result
View All Result
Home Analyst Actions

Nektar Therapeutics (NKTR)’s recent price decline sees it further from the 1-year target. Can it reach the target soon?

by Justin Shaw
June 25, 2020
in Analyst Actions
0
0
SHARES
12
VIEWS
Share on FacebookShare on Twitter

Nektar Therapeutics (NASDAQ:NKTR) went down by -3.83% during the previous trading session, and it is maintaining the win ahead of Wednesday’s trading session. The share price of the Biotechnology giant went up by $22.09 to trade ended Wednesday trading at $22.97. This is down from the $22.97 price recorded on Tuesday’s trading session. Its performance from the start of the year has also been positive, with NKTR up by 2.34% year-to-date.

Nektar Therapeutics (NKTR) started the day trading at $22.94 and recorded an intraday high of $23.09. It also recorded an intraday low of $22.06 during Wednesday’s trading session. Nektar Therapeutics is a very active stock that recorded a trading volume that is more than 2.82% of the average daily trading volume on Wednesday. The stock’s trading volume on Wednesday was 1275936, which is more than 2.82 of the total average daily trading volume of 1.24 million.

Nektar Therapeutics (NASDAQ:NKTR) 2020 Performance Impressive

The increase in NKTR’s stock price on Wednesday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of NKTR currently stands at $36.85, which is higher than the current trading price of the stock by 40.05%. However, NKTR’s current trading price is -62.07% lower than the 52-week low price of $13.63. In terms of trading volume, Nektar Therapeutics currently experienced healthy participation during the last trading session. 1275936 shares of Nektar Therapeutics were traded on the stock exchange on Wednesday, which is more than 2.82% of the 1.24 million average trading volume of the stock.

The performance of the stock has been positive over the past year. NKTR’s performance over the past one year has seen it plunge by -36.19%, while the stock has gone up by 1.10% in the last six months. The quarterly performance of NKTR currently stands at 30.48%, and it is down by -3.07% in the last month. The only positive figure was from the weekly performance, which currently reads 1.75%. At the time of writing NKTR’s report, the company has a total market cap of $3.79B, making it one of the largest publicly-traded companies in the world.Nektar Therapeutics also has over 723 employees all over the world.

NKTR Insider Activities

For Nektar Therapeutics, insiders hold 99.49% of all company shares. The insider transactions over the past six months are down by -2.10%. During that period, insiders bought 37,500 shares in 1 transactions. In that same period, insiders sold 130,203 of their shares in 20 transactions. After these transactions, insiders at Nektar Therapeutics now hold 2.09M shares, which is over 99.49% of the total company stocks. Institutional investors currently hold a large chunk of the NKTR shares, as they control 1.17% of the company’s total stock.

NKTR Fundamental Analysis

For Nektar Therapeutics, the stock’s diluted earnings per share (EPS) stands at -2.62. In the coming year, analysts expect the EPS to be -2.44. The EPS growth will slow down over the next five years to -7.30% after plunging by -42.70% in the previous five years. In terms of revenue, Nektar Therapeutics’s quarterly sales (YOY) is shrinking at -0.69, which is higher than the average annual revenue of -42.70% over the past half a decade.

The Return on Investment (ROI) on Nektar Therapeutics’s stock currently stands at -26.60%. The gross margin of the company is 85.60%.

NKTR Analysts Prediction

The H.C. Wainwright has a Neutral rating for Nektar Therapeutics, predicting the stock price to stay between $32 and $26. Goldman reiterate their Neutral position on the stock ($18 and $20)

Analysts at Mizuho believe that NKTR is Buy, and they have a price target of between $21 and $35. Goldman and H.C. Wainwright also believe that Nektar Therapeutics’s stock is outperforming at the moment.

NKTR Technical Analysis

The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of NKTR currently stands at 0.30%, while the SMA50 is 4.66%. The biggest one is the SMA200, which is currently reading 9.75% ahead of Wednesday’s trading session. The Relative Strength Index of this stock is 51.57.

Tags: NASDAQ:NKTRNektar TherapeuticsNKTRNKTR stock

Recommended Stories

Lyft Inc. [LYFT] Can’t Seem to Gain Investor Confidence as Volume Dips to 2092901

October 5, 2020

Here’s Why DXC Technology Company [DXC] Stock Traded -0.38 Lower

September 24, 2020

With an Enterprise Value of $755.13M, Here is Why We Love LSB Industries Inc. [LXU]

October 9, 2020

Popular Stories

  • Sorrento Therapeutics Inc. [SRNE] is One of the Best Plays in Healthcare and This Proves It

    0 shares
    Share 0 Tweet 0
  • Heat Biologics Inc. [HTBX] is One of the Best Plays in Healthcare and This Proves It

    0 shares
    Share 0 Tweet 0
  • Heat Biologics Inc. [HTBX] Is Skyrocketing 13.15% on Pure Fundamentals

    0 shares
    Share 0 Tweet 0
  • BlackBerry Limited [BB] is a Top Ten Buy with Quarterly Revenues of 999.00M

    0 shares
    Share 0 Tweet 0
  • Impressive Profit Margins of -5.80% Raise Bull Flags for General Electric Company [GE]

    0 shares
    Share 0 Tweet 0

NewsBur.com

Newsbur.com is an Economic news website, which offers broad information about the Stock markets and Equities. The major emphasis of this platform is to present, the most practical recommendation for public and private capital sharing, both in the form of updates and detailed analysis.

Recent Posts

  • After-Hours Trading Alert: Amgen Inc. [AMGN] is Up 0.85% After the Bell
  • Has Dynatrace Inc. [DT] Completely Outpaced Other Companies in the Technology This Year?
  • Why Applied Materials Inc. [AMAT]’s 1.55% Drop is No Cause for Alarm

Categories

  • Analyst Actions
  • Market News
  • Morning News
  • Trending Stocks
  • Uncategorized

© 2020 Copyright © All Rights Reserved.

No Result
View All Result
  • Home
  • Market News
  • Morning News
  • Analyst Actions
  • Trending Stocks

© 2020 Copyright © All Rights Reserved.